IMCD Group is in distribution partnership with Milan-based FIS (Fabbrica Italiana Sintetici) for their range of active pharmaceutical ingredients (APIs), in particular: anxiolytics, anticonvulsants, antidepressants, analgesics, anti- inflammatory agents, antibacterials, antifungals, cardiovascular drugs, diuretics, oncological products and hormones.
The new deal covers the following territories: Hungary, Slovenia, Serbia, Croatia, Macedonia, Bosnia and Herzegovina, Albania, Australia and New Zealand. The successful partnership of the two companies already covers a large number of countries in Maghreb, Central and Eastern Europe, most CIS countries and Russia and Austria.
Anne-Claire Bizet, European API Development Manager, IMCD said, “We are delighted about this new partnership at IMCD Business Group Pharmaceuticals, as this is the first time IMCD has an agency for an API manufacturer in Australia and New Zealand. APIs are a great complement to our comprehensive excipient portfolio which makes our offer to the pharma market complete.”
FIS has custom synthesis as their core business, thus having the exclusive production of intermediates, advanced intermediates and APIs for leading pharma companies. FIS provides a wide array of integrated services to the customer, including process research and development, optimisation, and scale-up facilities to support both validation and commercial launch.
IMCD Pharmaceutical Business Group is the number one distributor of pharma ingredients in Europe, supplying a comprehensive range of excipients, active ingredients, speciality solvents, process chemicals and intermediates. IMCD’s team of high-calibre pharmacists across the Group work closely with principal partners to provide expert formulation support and advice, focusing on key project development to deliver innovative solutions. Furthermore, IMCD’s commitment to conduct regular seminars ensures that all customer requirements are met and target objectives can be agreed upon.
EP News Bureau – Mumbai